Potential Reduction in Adverse Events and Cost with Novel Anticoagulants among Patients with Acute Limb Ischemia.

Scott FreemanPiper WilliamsAnna E BarónMary E PlomondonStephen W Waldo

Published in: International journal of vascular medicine (2022)

Among patients with ALI, treatment with rivaroxaban could result in a significant reduction in adverse cardiovascular events. The reduction in events would in turn lead to significant decreases in healthcare spending for this population.

Keyphrases

cardiovascular events
healthcare
coronary artery disease
cardiovascular disease
atrial fibrillation
pulmonary embolism
risk assessment
human health
replacement therapy
smoking cessation